NASH Clinical Trials

40 recruitingLast updated: June 18, 2026

There are 40 actively recruiting nash clinical trials across 41 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3. Top locations include San Antonio, Texas, United States, Jerusalem, Israel, Chandler, Arizona, United States. Updated daily from ClinicalTrials.gov.


NASH Trials at a Glance

40 actively recruiting trials for nash are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Not Applicable with 11 trials, with the heaviest enrollment activity in San Antonio, Jerusalem, and Chandler. Lead sponsors running nash studies include Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 89bio, Inc., and Akero Therapeutics, Inc.

Browse nash trials by phase

Treatments under study

About NASH Clinical Trials

Looking for clinical trials for NASH? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NASH trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NASH clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 40 trials

Recruiting
Phase 3

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled322 locationsNCT06528314
Recruiting
Phase 3

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

MASH With FibrosisNASH With Fibrosis
Akero Therapeutics, Inc1,650 enrolled356 locationsNCT06215716
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled349 locationsNCT06318169
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled303 locationsNCT06419374
Recruiting
Not Applicable

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis
University of Minnesota48 enrolled4 locationsNCT03587831
Recruiting

A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

NAFLD - Non-Alcoholic Fatty Liver DiseaseNAFLD and NASHNAFLD Cirrhosis
The Affiliated Hospital of Hangzhou Normal University20,000 enrolled1 locationNCT07241195
Recruiting
Phase 2

Digoxin In NASH (CODIN)

MASLDMASH - Metabolic Dysfunction-Associated SteatohepatitisFatty Liver Disease+5 more
Yale University144 enrolled2 locationsNCT06588699
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Not Applicable

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

NASH - Nonalcoholic Steatohepatitis
Perspectum225 enrolled7 locationsNCT04054310
Recruiting
Not Applicable

A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients

SurgeryObesityCirrhosis+1 more
University Hospital, Lille100 enrolled1 locationNCT03472157
Recruiting

Androgens and NAFLD Longitudinal Cohort Study

PCOSNAFLDNASH
University of California, San Francisco150 enrolled2 locationsNCT06124261
Recruiting
Phase 2

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)

NASH
Cascade Pharmaceuticals, Inc120 enrolled8 locationsNCT07198386
Recruiting
Phase 1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Not Applicable

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

Non alcoholic steato hepatitis (NASH)Liver Fibrosis/NASHMetabolic dysfunction–associated steatotic liver disease (MASLD)
Université de Sherbrooke36 enrolled1 locationNCT06843148
Recruiting

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

Obesity, MorbidNASH - Nonalcoholic SteatohepatitisChronic Inflammation
Mayo Clinic60 enrolled1 locationNCT04232566
Recruiting
Not Applicable

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Insulin Sensitivity/ResistanceObesityInsulin Resistance+16 more
Pichamol Jirapinyo, MD, MPH132 enrolled2 locationsNCT06138821
Recruiting
Not Applicable

Evaluation of Risk of hEpatocellular Carcinoma

Genetic PredispositionHCCNASH
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico500 enrolled1 locationNCT06523179
Recruiting
Phase 1

To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects

NASH
BAR Pharmaceuticals s.r.l.52 enrolled1 locationNCT06705998
Recruiting
Phase 2

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Nonalcoholic Steatohepatitis (NASH)
Polaris Group60 enrolled10 locationsNCT05842512
Recruiting

Blood Collection Biorepository for Liver Disease Research

CirrhosisFibrosisHepatitis B+5 more
State University of New York at Buffalo1,000 enrolled1 locationNCT03025074